Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 6071031, 11 pages
https://doi.org/10.1155/2017/6071031
Research Article

Recovery following Thyroxine Treatment Withdrawal, but Not Propylthiouracil, Averts In Vivo and Ex Vivo Thyroxine-Provoked Cardiac Complications in Adult FVB/N Mice

1Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH, USA
2Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH, USA
3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Cairo, Egypt

Correspondence should be addressed to Paul M. L. Janssen; ude.uso@01.nessnaj and Mohammad T. Elnakish; ude.uso@1.hsikanle

Received 20 March 2017; Revised 5 June 2017; Accepted 8 June 2017; Published 16 July 2017

Academic Editor: Natale Daniele Brunetti

Copyright © 2017 Nancy S. Saad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C.-W. Siu, X.-H. Zhang, C. Yung et al., “Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study,” The Journal of Clinical Endocrinology Metabolism, vol. 92, no. 5, pp. 1736–1742, 2007. View at Publisher · View at Google Scholar
  2. C.-W. Siu, V. Pong, X. Zhang et al., “Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism,” Heart Rhythm, vol. 6, no. 2, pp. 169–173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C.-W. Siu, C.-Y. Yeung, C.-P. Lau, A. W. C. Kung, and H.-F. Tse, “Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism,” Heart, vol. 93, no. 4, pp. 483–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Kuzman, K. A. Vogelsang, T. A. Thomas, and A. M. Gerdes, “L-Thyroxine activates Akt signaling in the heart,” Journal of Molecular and Cellular Cardiology, vol. 39, no. 2, pp. 251–258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Kuzman, T. A. Thomas, K. A. Vogelsang, S. Said, B. E. Anderson, and A. M. Gerdes, “Effects of induced hyperthyroidism in normal and cardiomyopathic hamsters,” Journal of Applied Physiology, vol. 99, no. 4, pp. 1428–1433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. F. E. S. Cruz, E. C. Cheriex, J. L. R. M. Smeets et al., “Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia,” Journal of the American College of Cardiology, vol. 16, no. 3, pp. 739–744, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. W. J. deGroot and J. J. Leonard, “Hyperthyroidism as a high cardiac output state,” American Heart Journal, vol. 79, no. 2, pp. 265–275, 1970. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Marcisz, G. Jonderko, T. Wróblewski, G. Kurzawska, and F. Mazur, “Left ventricular mass in patients with hyperthyroidism,” Medical Science Monitor, vol. 12, no. 11, pp. CR481–CR486, 2006. View at Google Scholar · View at Scopus
  9. B. Biondi, “Mechanisms in endocrinology: heart failure and thyroid dysfunction,” European Journal of Endocrinology, vol. 167, no. 5, pp. 609–618, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Osman, J. A. Franklyn, R. L. Holder, M. C. Sheppard, and M. D. Gammage, “Cardiovascular Manifestations of Hyperthyroidism Before and After Antithyroid Therapy. A Matched Case-Control Study,” Journal of the American College of Cardiology, vol. 49, no. 1, pp. 71–81, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. V. Dhadke and V. N. Dhadke, “Reversible cardiomyopathy,” Journal of Association of Physicians of India, vol. 54, pp. 740-741, 2006. View at Google Scholar · View at Scopus
  12. W.-S. Yue, B.-H. Chong, X.-H. Zhang et al., “Hyperthyroidism-induced left ventricular diastolic dysfunction: implication in hyperthyroidism-related heart failure,” Clinical Endocrinology, vol. 74, no. 5, pp. 636–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Brandt, A. Green, L. Hegedüs, and T. H. Brix, “A critical review and meta-analysis of the association between overt hyperthyroidism and mortality,” European Journal of Endocrinology, vol. 165, no. 4, pp. 491–497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Franklyn, P. Maisonneuve, M. C. Sheppard, J. Betteridge, and P. Boyle, “Mortality after the treatment of hyperthyroidism with radioactive iodine,” The New England Journal of Medicine, vol. 338, no. 11, pp. 712–718, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Hall, G. Lundell, and L.-E. Holm, “Mortality in patients treated for hyperthyroidism with iodine-131,” Acta Endocrinologica, vol. 128, no. 3, pp. 230–234, 1993. View at Google Scholar · View at Scopus
  16. L. Tomisti, G. Materazzi, L. Bartalena et al., “Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 10, pp. 3515–3521, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Ryödi, J. Salmi, P. Jaatinen et al., “Cardiovascular morbidity and mortality in surgically treated hyperthyroidism - A nation-wide cohort study with a long-term follow-up,” Clinical Endocrinology, vol. 80, no. 5, pp. 743–750, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. I. J. Chopra, T.-S. Huang, R. E. Hurd, and D. H. Solomon, “A study of cardiac effects of thyroid hormones: Evidence for amelioration of the effects of thyroxine by sodium ipodate,” Endocrinology, vol. 114, no. 6, pp. 2039–2045, 1984. View at Publisher · View at Google Scholar · View at Scopus
  19. Y.-Y. Wang, S. Morimoto, C.-K. Du et al., “Up-regulation of type 2 iodothyronine deiodinase in dilated cardiomyopathy,” Cardiovascular Research, vol. 87, no. 4, pp. 636–646, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. N. S. Hübner, A. Merkle, B. Jung, D. von Elverfeldt, and L.-A. Harsan, “Analysis of left ventricular function of the mouse heart during experimentally induced hyperthyroidism and recovery,” NMR in Biomedicine, vol. 28, no. 1, pp. 116–123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. C. S. Hoefig, L. Harder, R. Oelkrug et al., “Thermoregulatory and cardiovascular consequences of a transient thyrotoxicosis and recovery in male mice,” Endocrinology, vol. 157, no. 7, pp. 2957–2967, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. M. T. Elnakish, L. Moldovan, M. Khan, H. H. Hassanain, and P. M. L. Janssen, “Myocardial Rac1 exhibits partial involvement in thyroxin-induced cardiomyocyte hypertrophy and its inhibition is not sufficient to improve cardiac dysfunction or contractile abnormalities in mouse papillary muscles,” Journal of Cardiovascular Pharmacology, vol. 61, no. 6, pp. 536–544, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. T. Elnakish, E. J. Schultz, R. L. Gearinger et al., “Differential involvement of various sources of reactive oxygen species in thyroxin-induced hemodynamic changes and contractile dysfunction of the heart and diaphragm muscles,” Free Radical Biology and Medicine, vol. 83, pp. 252–261, 2015. View at Publisher · View at Google Scholar
  24. N. S. Saad, K. Floyd, A. A. E. Ahmed, P. J. Mohler, P. M. L. Janssen, and M. T. Elnakish, “The effect of sorafenib, tadalafil and macitentan treatments on thyroxin-induced hemodynamic changes and cardiac abnormalities,” PLoS ONE, vol. 11, no. 4, Article ID e0153694, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. M. T. Elnakish, M. D. H. Hassona, M. A. Alhaj et al., “Rac-induced left ventricular dilation in thyroxin-treated zmracd transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis,” PLoS ONE, vol. 7, no. 8, Article ID e42500, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Kuzman, T. D. O'Connell, and A. M. Gerdes, “Rapamycin prevents thyroid hormone-induced cardiac hypertrophy,” Endocrinology, vol. 148, no. 7, pp. 3477–3484, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. E. K. Rodriguez, W. C. Hunter, M. J. Royce, M. K. Leppo, A. S. Douglas, and H. F. Weisman, “A method to reconstruct myocardial sarcomere lengths and orientations at transmural sites in beating canine hearts,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 263, no. 1, part 2, pp. H293–H306, 1992. View at Google Scholar · View at Scopus
  28. H. Nakamura, J. Y. Noh, K. Itoh et al., “Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 6, pp. 2157–2162, 2007. View at Google Scholar
  29. A. C. Freitas Ferreira, L. de Carvalho Cardoso, D. Rosenthal, and D. Pires de Carvalho, “Thyroid Ca2+/NADPH-dependent H2O2 generation is partially inhibited by propylthiouracil and methimazole,” European Journal of Biochemistry, vol. 270, no. 11, pp. 2363–2368, 2003. View at Publisher · View at Google Scholar
  30. A. C. Bianco and B. W. Kim, “Deiodinases: implications of the local control of thyroid hormone action,” The Journal of Clinical Investigation, vol. 116, no. 10, pp. 2571–2579, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Jabbar, A. Pingitore, S. H. S. Pearce, A. Zaman, G. Iervasi, and S. Razvi, “Thyroid hormones and cardiovascular disease,” Nature Reviews Cardiology, vol. 14, no. 1, pp. 39–55, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. H. L. Schwartz, M. I. Surks, and J. H. Oppenheimer, “Quantitation of extrathyroidal conversion of L-thyroxine to 3,5,3'-triiodo-L-thyronine in the rat,” Journal of Clinical Investigation, vol. 50, no. 5, pp. 1124–1130, 1971. View at Publisher · View at Google Scholar · View at Scopus
  33. J. H. Oppenheimer, H. L. Schwartz, and M. I. Surks, “Propylthiouracil inhibits the conversion of L-thyroxine to L-triiodothyronine. An explanation of the antithyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone.,” Journal of Clinical Investigation, vol. 51, no. 9, pp. 2493–2497, 1972. View at Publisher · View at Google Scholar · View at Scopus
  34. D. L. Geffner, M. Azukizawa, and J. M. Hershman, “Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man,” Journal of Clinical Investigation, vol. 55, no. 2, pp. 224–229, 1975. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Saberi, F. H. Sterling, and R. D. Utiger, “Reduction in extrathyroidal triiodothyronine production by propylthiouracil in man,” Journal of Clinical Investigation, vol. 55, no. 2, pp. 218–223, 1975. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Croteau, J. C. Davey, V. A. Galton, and D. L. St. Germain, “Cloning of the mammalian type II iodothyronine deiodinase. A selenoprotein differentially expressed and regulated in human and rat brain and other tissues,” Journal of Clinical Investigation, vol. 98, no. 2, pp. 405–417, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Dentice, C. Morisco, M. Vitale, G. Rossi, G. Fenzi, and D. Salvatore, “The different cardiac expression of the type 2 iodothyronine deiodinase gene between human and rat is related to the differential response of the dio2 genes to Nkx-2.5 and GATA-4 transcription factors,” Molecular Endocrinology, vol. 17, no. 8, pp. 1508–1521, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Abuid and P. R. Larsen, “Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents,” Journal of Clinical Investigation, vol. 54, no. 1, pp. 201–208, 1974. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Wangensteen, I. Rodríguez-Gómez, J. M. Moreno, M. Álvarez-Guerra, A. Osuna, and F. Vargas, “Effects of chronic treatment with 7-nitroindazole in hyperthyroid rats,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 291, no. 5, pp. R1376–R1382, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Rodríguez-Gómez, J. Sainz, R. Wangensteen et al., “Increased pressor sensitivity to chronic nitric oxide deficiency in hyperthyroid rats,” Hypertension, vol. 42, no. 2, pp. 220–225, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. I. Rodríguez-Gómez, R. Wangensteen, J. M. Moreno, V. Chamorro, A. Osuna, and F. Vargas, “Effects of chronic inhibition of inducible nitric oxide synthase in hyperthyroid rats,” American Journal of Physiology—Endocrinology and Metabolism, vol. 288, no. 6, pp. E1252–E1257, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Vazir, B. J. Whitehouse, G. P. Vinson, and E. McCredie, “Effects of prolonged ACTH treatment on adrenal steroidogenesis and blood pressure in rats,” Acta Endocrinologica, vol. 97, no. 4, pp. 533–542, 1981. View at Google Scholar · View at Scopus
  43. E. O. Johnson, T. C. Kamilaris, A. E. Calogero, P. W. Gold, and G. P. Chrousos, “Experimentally-induced hyperthyroidism is associated with activation of the rat hypothalamic-pituitary-adrenal axis,” European Journal of Endocrinology, vol. 153, no. 1, pp. 177–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. M.-J. Lo, S-W. Wang, and M.-M. Kau, “Pharmacological effects of propylthiouracil on corticosterone secretion in male rats,” Journal of investigative medicine: the official publication of the American Federation for Clinical Research, vol. 46, no. 9, pp. 444–452, 1998. View at Google Scholar
  45. Z. Serfozo, P. B. Kiss, Z. Kukor et al., “Thyroid hormones affect the level and activity of nitric oxide synthase in rat cerebral cortex during postnatal development,” Neurochemical Research, vol. 33, no. 3, pp. 569–578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Ohba, M. K.-S. Leow, B. K. Singh et al., “Desensitization and incomplete recovery of hepatic target genes after chronic thyroid hormone treatment and withdrawal in male adult mice,” Endocrinology, vol. 157, no. 4, pp. 1660–1672, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. J. J. Fahrenfort, A. M. L. Wilterdink, and E. A. Van Der Veen, “Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism,” Psychoneuroendocrinology, vol. 25, no. 2, pp. 201–211, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. M. T. Elnakish, H. H. Hassanain, and P. M. L. Janssen, “Vascular remodeling-associated hypertension leads to left ventricular hypertrophy and contractile dysfunction in profilin-1 transgenic mice,” Journal of Cardiovascular Pharmacology, vol. 60, no. 6, pp. 544–552, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. I. J. Chopra, A. J. van Herle, S. G. Korenman, S. Viosca, and S. Younai, “Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis,” Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 7, pp. 2178–2180, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. I. Klein and S. Danzi, “Thyroid disease and the heart,” Circulation, vol. 116, no. 15, pp. 1725–1735, 2007. View at Publisher · View at Google Scholar · View at Scopus